HDL profiling in patients with deep vein thrombosis

HDL profiling in patients with deep vein thrombosis - The PROFILE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34805

Enrollment

Registered

2010-03-03

Start date

2009-12-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lipiden trombose venous thrombo-embolism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Cases: All patients with a first episode of a (objectified) deep vein thrombosis aged 18 years and older are eligible for participation. Controls: Age and sex-matched individuals with complaints of the leg, in whom a DVT has been exluded by means of ultrasonography.

Exclusion criteria

Exclusion criteria: Those patienten with a previous venous thrombo-embolism, malignancy or other medical indication requiring long term anticoagulant treatment. Furthermore those patients with a history of cardiovascular disease or those using lipid lowering medication are not eligible for participation.

Design outcomes

Primary

Measure	Time frame
Protein profiling of HDL will be done using SELDI-TOF mass spectrometry. Additional laboratory testing will include determination of lipid spectrum (HDL-c, LDL-c, triglycerides, apo A1, apoB, total cholesterol), measurements of coagulation markers (aPTT, PT, protein S, activated protein C, F1+2, factor VIII, vWF), markers of fibrinolysis (ddimer) and inflammatory markers (CRP, Il-6, TNF-a, MCP, Leucocytes, SAA).	—

Measure

Time frame

Protein profiling of HDL will be done using SELDI-TOF mass spectrometry. Additional laboratory testing will include determination of lipid spectrum (HDL-c, LDL-c, triglycerides, apo A1, apoB, total cholesterol), measurements of coagulation markers (aPTT, PT, protein S, activated protein C, F1+2, factor VIII, vWF), markers of fibrinolysis (ddimer) and inflammatory markers (CRP, Il-6, TNF-a, MCP, Leucocytes, SAA).

—

Secondary

Measure	Time frame
Additional laboratory testing will include determination of lipid spectrum (HDL-c, LDL-c, triglycerides, apo A1, apoB, total cholesterol), measurements of coagulation markers (aPTT, PT, protein S, activated protein C, F1+2, factor VIII, vWF), markers of fibrinolysis (ddimer) and inflammatory markers (CRP, Il-6, TNF-a, MCP, Leucocytes, SAA).	—

Countries

Netherlands

Outcome results